<DOC>
	<DOCNO>NCT00002175</DOCNO>
	<brief_summary>To evaluate efficacy dinitrochlorobenzene ( DNCB ) patient early HIV infection monitor immunologic parameter serum HIV RNA . To facilitate understanding possible alteration immunological status HIV+ patient cohort .</brief_summary>
	<brief_title>Epicutaneous 1-Chloro-2 , 4-Dinitrobenzene ( DNCB ) Patch HIV Infection .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Inclusion Criteria Patients must : EITHER HIV negative document HIV+ ELISA Western blot test . For HIV+ patient : Patients must fail meet AIDSdefining criterion . CD4 lymphocyte count 200 500 cells/mm3 . Exclusion Criteria Coexisting Condition : Excluded : Patients obvious ultra violet ( UV ) irradiate skin damage treatment site . Concurrent Medication : Excluded : Patients likely commence antiretrovirals within 6month study period . Patients use immunomodulator therapy alternative therapy . Patients likely require chemotherapy course study . Concurrent Treatment : Excluded : Patients likely require significant UV light exposure study period . Patients likely require radiation therapy course study . Prior Medication : Excluded : Prior exposure DNCB . Patients used antiretroviral medication within previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 1999</verification_date>
	<keyword>Cohort Studies</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Administration , Cutaneous</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Dinitrobenzenes</keyword>
</DOC>